eligibility_summary
Eligibility: Metastatic/unresectable ovarian, endometrial (non-sarcoma), triple-negative breast (TNBC), or NSCLC. Part A: after prior beneficial systemic therapy and not amenable to local therapy. Part B: measurable disease per RECIST 1.1. Exclude prior anti-PTK7 therapy, progression on auristatin-ADC as most recent line, recent other cancers (<3 yrs) unless low risk, active CNS mets (unless treated/stable, off steroids >=7 days), significant corneal disease. Additional criteria may apply.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06171789 tested GEN1107 (also called PRO1107), a protein tyrosine kinase 7 (PTK7)–targeted antibody‑drug conjugate (ADC), in advanced solid tumors (ovarian, endometrial, TNBC, NSCLC, gastroesophageal, urothelial). Drug type/mechanism: monoclonal antibody–based ADC that binds the cell‑surface receptor PTK7, is internalized, and releases an attached cytotoxic payload to induce tumor cell death. Cells/pathways targeted: PTK7‑expressing malignant cells, PTK7 functions as a receptor/co‑receptor linked to Wnt/planar cell polarity signaling, a pathway associated with tumor growth and metastasis. Study status: terminated, sponsor discontinued development due to an unfavorable overall benefit‑risk profile.